The waiver removes restrictions that would have blocked Glucotrack from issuing additional equity through variable-rate or other financings for up to 90 days, effectively reopening the door for capital raises. Monitor for any subsequent equity offering announcement, which would signal near-term dilution. The stockholder vote required for warrant exercisability is a key catalyst to watch.
Price Chart
Executive Summary
Glucotrack entered into a waiver agreement with holders of existing warrants from a July 2026 securities purchase agreement, waiving equity issuance restrictions and variable-rate transaction price-adjustment rights. In exchange, the company will issue new warrants to purchase an aggregate of 406,198 shares of common stock at $7.50 per share, exercisable only after stockholder approval per Nasdaq rules. The filing clears the path for future equity financing but adds potential future dilution of 406,198 shares.
Key Facts
- Waiver terminates the 90-day equity issuance restriction under Section 5.10(a) of the July 14, 2026 Securities Purchase Agreement
- Waiver terminates the variable-rate transaction (VRT) exercise price adjustment right under Section 3(e) of the existing warrants
- Company will issue new warrants to purchase 406,198 shares of common stock at $7.50 per share
- New warrants expire in 5 years and are not exercisable until stockholder approval is obtained under Nasdaq Listing Rule 5635
- New warrants include a 9.99% beneficial ownership limitation and a floor price equal to 20% of the closing sale price on the issuance date
- Existing warrants from the July 2026 purchase agreement remain outstanding
Financial Impact
Potential future dilution of 406,198 shares upon exercise of new warrants; no immediate cash impact as warrants are not yet exercisable
Risk Factors
- Potential future dilution of 406,198 shares if warrants are exercised
- Stockholder approval may not be obtained, leaving warrants unexercisable
- Company may pursue dilutive equity financing now that restrictions are lifted
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047582 |
| Exhibit: ex10-1.htm | 0001493152-26-047582 |
| Document: form8-k.htm | 0001493152-26-047582 |
| Document: 0001493152-26-047582-index-headers.html | 0001493152-26-047582 |
| Document: 0001493152-26-047582-index.html | 0001493152-26-047582 |
| Document: 0001493152-26-047582.txt | 0001493152-26-047582 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.4032 | awaiting T+60 | — | $1.61 (−299.31%) |
Oct 19, 2026 7d ago | 8-K | $0.6511 | awaiting T+60 | — | $1.61 (+147.27%) |
Oct 13, 2026 13d ago | S-1/A | $0.8873 | awaiting T+60 | — | $1.61 (−81.45%) |
Oct 13, 2026 13d ago | 425 | $0.8873 | awaiting T+60 | — | $1.61 (+81.45%) |
Sep 28, 2026 28d ago | 8-K | $1.74 | awaiting T+60 | — | $1.61 (−7.47%) |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | $1.61 (+11.54%) |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | $1.61 (+11.54%) |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | $1.61 (−20.69%) |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | $1.61 (−20.69%) |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | $1.61 (−30.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers